Press Releases

Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

EAGAN, MN — May 31, 2017 — Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows: Session Date & Time: Monday, June 5, 2017,...

Read More


Biothera Announces Three Presentations at Upcoming American Association for Cancer Research Annual Meeting

EAGAN, MN — March 27, 2017 — Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research. Poster Presentations: Session Date & Time:  Monday, April 3, 8:00 AM – 12:00 PM Eastern...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More


Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More


Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017

EAGAN, MN — February 15, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual Molecular Medicine Tri-Conference, taking place at the Moscone North Convention Center, San Francisco, February 19-24, 2017. Jeremy R. Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera Pharmaceuticals, will present data showing that...

Read More


Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC) EAGAN, MN — August 24, 2016 — Biothera Pharmaceuticals, Inc. today announced...

Read More


Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck’s Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer

EAGAN, MN — December 10, 2015 — Biothera Pharmaceutical Inc., today announced plans for a Phase 1b/2 clinical study in non-small lung cancer (NSCLC) patients to evaluate the ability of Biothera’s Imprime PGG to enhance responses to pembrolizumab (Keytruda®), the anti-PD-1 antibody from Merck (NYSE:MRK), known as MSD outside the United States and Canada. Merck will provide funding and clinical supplies of pembrolizumab for the...

Read More



Page 3 of 3123